Climate Change Denier on Fossil Fuel Payroll

A leading scientific voice among global warming skeptics received funding from the energy industry while publishing claims that climate change is not driven by human activity.

By | February 23, 2015

WIKIMEDIA, U.S. NATIONAL ARCHIVES AND RECORDS ADMINISTRATIONWei-Hock “Willie” Soon, a solar physicist at the Harvard-Smithsonian Center for Astrophysics (CfA), received significant funding from energy companies while publishing studies that suggested solar activity, rather than human-generated greenhouse gasses, was causing dramatic shifts in global climate. Soon, whose work is frequently cited by conservative politicians to support their skepticism of the human role in climate change, accepted more than $1.2 million from fossil-fuel companies over the past decade, according to documents obtained by environmental group Greenpeace under the Freedom of Information Act. During that same period, Soon failed to disclose any the financial conflicts of interests to publishers of his scientific studies, violating journals’ ethical guidelines in several cases, The New York Times reported.

Though the vast majority of climate scientists agree that the Earth’s climate is changing as a result of human activities that increase the amounts of greenhouse gasses into the atmosphere, researchers like Soon foment debate by publishing alternate hypotheses or denials. “The whole doubt-mongering strategy relies on creating the impression of scientific debate,” Naomi Oreskes, a historian of science at Harvard, told the Times. “Willie Soon is playing a role in a certain kind of political theater.”

The CfA announced that it would launch a formal inquiry into Soon’s failure to properly report the energy-industry funding, some of which was also funneled to the CfA itself, according to the newly divulged documents. The investigation will take place even though the institute doesn’t have an official policy mandating that its researchers report disclose funding sources when they publish. “We want to get the facts straight,” CfA Director Charles Alcock told Nature. “If there is evidence of failure to disclose, yes, we have a problem.”

According to the documents obtained by Greenpeace, Soon submitted annual reports to the Southern Company, a Birmingham-Alabama-based energy firm, in which he referred to nine journal articles as “deliverables,” after the company provided at least $400,000 to the researcher. Soon did not mention support from Southern in any of the articles.

Update (March 2): In a statement, Soon today said he has “never been motivated by financial gain to write any scientific paper,” and denies having “hidden grants or any other alleged conflict of interest.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Rdzign

Rdzign

Posts: 1

February 24, 2015

The Title of this article says everything it needs to about the hypocrisy of the author and probably The Scientist too.  The accusations that a scientist has recieved income from "big Energy" is a fair point, but the fact that he is called a "climate change denier" right in the title, this being a completely misleading statement as those who differ on climate change differ on cause not the fact that there is change. this type of propaganda no matter your view comes from simpltons and only works on those unwilling to educate themselves beyond reading titles. Shame on you The Scientist.

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Long-term Study Finds That the Pesticide Glyphosate Does Not Cause Cancer
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech